| 7.66 0.519 (7.26%) | 03-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.44  |
1-year : | 11.03 |
| Resists | First : | 8.08 |
Second : | 9.44 |
| Pivot price | 1.45 |
|||
| Supports | First : | 3.37 |
Second : | 0.46 |
| MAs | MA(5) : | 3.28 |
MA(20) : | 1.23 |
| MA(100) : | 0.79 |
MA(250) : | 0.76 |
|
| MACD | MACD : | 0.9 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 78.1 |
D(3) : | 61.2 |
| RSI | RSI(14): 98.4 |
|||
| 52-week | High : | 8.08 | Low : | 0.46 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ XLO ] has closed above the upper band by 16.5%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 3371.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 8.1 - 8.13 | 8.13 - 8.16 |
| Low: | 6.61 - 6.64 | 6.64 - 6.67 |
| Close: | 7.6 - 7.65 | 7.65 - 7.71 |
Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
Mon, 16 Mar 2026
Xilio Therapeutics (NASDAQ:XLO) Sees Unusually-High Trading Volume - Here's What Happened - MarketBeat
Thu, 12 Mar 2026
Xilio Therapeutics (Nasdaq: XLO) enacts 1-for-14 reverse stock split - Stock Titan
Thu, 12 Mar 2026
Cancer biotech Xilio enacts 1-for-14 reverse split to regain Nasdaq compliance - Stock Titan
Mon, 09 Mar 2026
Xilio Therapeutics posts investor presentation highlighting pipeline, $137.5M cash and upcoming INDs - TradingView
Mon, 02 Mar 2026
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference - GlobeNewswire
Mon, 02 Mar 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Globe and Mail
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 73 (M) |
| Shares Float | 16 (M) |
| Held by Insiders | 35.3 (%) |
| Held by Institutions | 42.4 (%) |
| Shares Short | 2,160 (K) |
| Shares Short P.Month | 2,090 (K) |
| EPS | -0.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.16 |
| Profit Margin | -183.9 % |
| Operating Margin | -10.2 % |
| Return on Assets (ttm) | -26.3 % |
| Return on Equity (ttm) | -908.3 % |
| Qtrly Rev. Growth | 742.5 % |
| Gross Profit (p.s.) | 0.35 |
| Sales Per Share | 0.43 |
| EBITDA (p.s.) | -0.58 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -12.56 |
| PEG Ratio | 0 |
| Price to Book value | -47.88 |
| Price to Sales | 17.69 |
| Price to Cash Flow | -32.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|